Tatva Chintan Pharma Stock Screener | Share Price & Fundamental Analysis
TATVA
Specialty Chemicals
Screen Tatva Chintan Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1339.70
▼
-49.10 (-3.54%)
Share Price BSE
₹1340.25
▼
-48.10 (-3.46%)
Market Cap
₹3,098.75 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
4.14
EPS (TTM)
₹2.44
Dividend Yield
0.07%
Debt to Equity
0.03
52W High
₹1588.70
52W Low
₹637.00
Operating Margin
8.00%
Profit Margin
0.92%
Revenue (TTM)
₹109.00
EBITDA
₹10.00
Net Income
₹1.00
Total Assets
₹836.00
Total Equity
₹739.00
Tatva Chintan Pharma Share Price History - Stock Screener Chart
Screen TATVA historical share price movements with interactive charts. Analyze price trends and patterns.
Tatva Chintan Pharma Company Profile - Fundamental Screener
Screen Tatva Chintan Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for TATVA shares.
Sector
Chemicals
Industry
Specialty Chemicals
Sub-Sector
Specialty Chemicals
Segment
E
ISIN
INE0GK401011
Tatva Chintan Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen TATVA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total Assets | 836 | 819 | 759 | 658 | 315 | 249 | 188 | 0 |
| Current Assets | 265 | 298 | 312 | 436 | 184 | 133 | 114 | 0 |
| Fixed Assets | 526 | 427 | 196 | 160 | 120 | 111 | 67 | 0 |
| Liabilities | ||||||||
| Total Liabilities | 836 | 819 | 759 | 658 | 315 | 249 | 188 | 0 |
| Current Liabilities | 1 | 2 | 5 | 14 | 31 | 44 | 35 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||
| Total Equity | 739 | 737 | 515 | 473 | 166 | 118 | 80 | 0 |
| Share Capital | 23 | 23 | 22 | 22 | 20 | 8 | 8 | 0 |
| Reserves & Surplus | 715 | 714 | 493 | 451 | 146 | 110 | 72 | 0 |
Screen TATVA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109 | 118 | 125 | 103 | 107 | 84 | 86 | 125 | 115 | 97 | 85 | 99 | 90 | 92 | 122 |
| Expenses | 99 | 100 | 101 | 83 | 93 | 78 | 79 | 112 | 93 | 76 | 73 | 77 | 73 | 79 | 103 |
| EBITDA | 10 | 19 | 23 | 20 | 14 | 6 | 7 | 14 | 22 | 21 | 12 | 22 | 17 | 13 | 19 |
| Operating Profit % | 8.00% | 15.00% | 18.00% | 16.00% | 12.00% | 7.00% | 8.00% | 10.00% | 19.00% | 21.00% | 13.00% | 22.00% | 17.00% | 12.00% | 15.00% |
| Depreciation | 7 | 9 | 9 | 6 | 7 | 7 | 7 | 3 | 6 | 7 | 7 | 2 | 2 | 2 | 2 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 0 | 1 | 1 | 1 | 2 |
| Profit Before Tax | 2 | 9 | 14 | 14 | 7 | -1 | 0 | 8 | 13 | 11 | 5 | 19 | 14 | 9 | 14 |
| Tax | 1 | 3 | 4 | 4 | 2 | 0 | 0 | -9 | 4 | 3 | 2 | 2 | 4 | 2 | 3 |
| Net Profit | 1 | 7 | 10 | 10 | 5 | -1 | 0 | 17 | 10 | 8 | 4 | 18 | 10 | 7 | 12 |
| EPS | 0.44 | 2.84 | 4.24 | 4.11 | 2.23 | -0.29 | 0.06 | 7.65 | 4.29 | 3.43 | 1.48 | 7.90 | 4.42 | 3.21 | 5.24 |
Tatva Chintan Pharma Cash Flow Screener - Liquidity Fundamentals
Screen TATVA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 25 | 98 | 28 | 20 | 20 | 25 | 7 | 13 |
| Investing Activities | -65 | -121 | -101 | -197 | -21 | -40 | -17 | -30 |
| Financing Activities | 17 | 31 | 38 | 235 | -5 | 10 | 17 | 7 |
| Net Cash Flow | -24 | 8 | -36 | 59 | -6 | -5 | 8 | -10 |
Screen TATVA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% |
| FII Holding | 3.39% | 3.26% | 3.30% | 3.36% | 3.33% | 3.37% | 3.65% | 4.21% |
| DII Holding | 3.86% | 5.11% | 5.46% | 6.34% | 6.82% | 10.63% | 12.84% | 13.06% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 18.29% | 17.47% | 16.92% | 16.33% | 15.95% | 12.44% | 10.49% | 9.38% |
| Other Holding | 2.44% | 2.14% | 2.30% | 1.95% | 1.87% | 1.54% | 1.00% | 1.33% |
| Shareholder Count | 73,331 | 76,792 | 78,393 | 79,009 | 79,623 | 73,912 | 73,730 | 74,519 |
Tatva Chintan Pharma Dividend Screener - Share Yield Analysis
Screen TATVA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.07% |
| 2024-March | ₹2.00 | 0.30% |
| 2023-March | ₹2.00 | 0.19% |
| 2022-March | ₹2.00 | 0.12% |
| 2021-March | ₹5.00 | 0.22% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Tatva Chintan Pharma Index Membership - Market Screener Classification
Screen TATVA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Tatva Chintan Pharma Market Events Screener - Corporate Actions
Screen TATVA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 1.00 /share | 42.95% | ||
| Dividend | ₹ 2.00 /share | -10.87% | ||
| Dividend | ₹ 2.00 /share | -20.78% | ||
| Annual General Meeting | NA | -2.87% | ||
| Dividend | ₹ 2.00 /share | 0.06% | ||
| Annual General Meeting | NA | -2.06% | ||
| 2025-10-31 | 2025-10-31 | Quarterly Result Announcement | NA | 5.47% |
| 2025-07-24 | 2025-07-24 | Quarterly Result Announcement | NA | 5.55% |
| 2025-05-02 | 2025-05-02 | Quarterly Result Announcement | NA | -7.28% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -3.45% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -5.26% |
Tatva Chintan Pharma Competitors Screener - Peer Comparison
Screen TATVA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Pidilite Industries | 149,533 | 67.12 | 13,388 | 6.91% | 2,096 | 51.21 |
| SRF | 90,626 | 56.34 | 14,826 | 12.13% | 1,251 | 57.47 |
| Gujarat Fluorochemicals | 40,369 | 59.21 | 4,853 | 10.61% | 546 | 62.46 |
| Navin Fluorine International | 30,388 | 68.32 | 2,393 | 12.83% | 289 | 52.18 |
| Himadri Speciality Chemical | 24,488 | 37.78 | 4,664 | 10.33% | 555 | 60.47 |
| Deepak Nitrite | 23,205 | 44.38 | 8,366 | 7.84% | 697 | 57.66 |
| Atul | 18,163 | 32.18 | 5,692 | 18.99% | 499 | 60.25 |
| BASF | 16,948 | 45.47 | 15,339 | 10.81% | 479 | 40.83 |
| Vinati Organics | 16,551 | 37.83 | 2,293 | 18.24% | 405 | 50.60 |
| Anupam Rasayan | 15,102 | 67.45 | 1,449 | -3.77% | 160 | 65.32 |
Tatva Chintan Pharma Company Announcements - News Screener
Screen TATVA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-31 | Closure of Trading Window | View |
| 2025-11-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-31 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-10-31 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-10-31 | Intimation Under Regulation 30 (5) Of The Securities And Exchange Board Of India ("SEBI") (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-10-31 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-10-31 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 31.10.2025 | View |
| 2025-10-31 | Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 2025 | View |
| 2025-10-24 | Clarification On Price Movement | View |
| 2025-10-23 | Clarification Sought from Tatva Chintan Pharma Chem Ltd | - |
| 2025-10-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |